Stay updated with the latest healthcare breakthroughs, including Otsuka’s sibeprenlimab 24-month eGFR data in IgA nephropathy.
News|Videos|December 25, 2024
Crisis Point: Benzene Concerns in Acne Care
Author(s)Tim Smith
In this episode of Crisis Point, this year’s news regarding benzene found in acne products is discussed by David Light, Neal Bhatia, MD, and Christopher Bunick, MD, PhD.
Advertisement
Advertisement
A March 6, 2024
Related to this article
Reena Mehra, MD, discusses a post hoc analysis in which AD109 reduced AHI4 by 59.6% in postmenopausal women vs 44.0% in non-menopausal participants.
In phase 3 INTREPID, lutikizumab beat placebo on HiSCR75 at week 16 and met all 8 ranked secondary end points in moderate to severe HS.
This Q&A interview segment with Harrison Nguyen, MD, MBA, MPH, highlights key points made during his 2026 Fall Clinical Dermatology meeting sessions.
In 1200 patients with solid tumors, creatinine-based eGFR identified CKD in 10.2% vs 18.9% by measured GFR, often missing chemotherapy dosing cutoffs.
Phase 2 BESTOW patient-reported outcomes show greater quality-of-life gains and fewer medication-related symptoms with tegoprubart vs tacrolimus at 1 year.
Katherine Tuttle, MD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to unpack new FIND-CKD finerenone analyses from ASN 2026.
Jicheng Lv, MD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to discuss 2-year TELIGAN data for telitacicept in IgAN.
Advertisement
Advertisement